Home » Topics » Hematologic, BioWorld Science

Hematologic, BioWorld Science
RSS

PhaseBio reports promising phase I results with ticagrelor reversal agent PB-2452

Sep. 25, 2018

Global phase III ALPS study of roxadustat meets primary endpoints

Sep. 21, 2018

Pharming receives complete response letter from FDA for Ruconest

Sep. 21, 2018

Efgartigimod phase II data in ITP support progression to phase III development

Sep. 17, 2018

Arrowhead Pharmaceuticals patents RNAi for thromboembolic disorders

Sep. 14, 2018

Verseon initiates phase I trial with anticoagulant VE-1902

Sep. 13, 2018

European Commission approves Veyvondi for adults with von Willebrand disease

Sep. 12, 2018

Positive results reported across multiple endpoints in ZENITH-1 trial of oral BCX-7353

Sep. 5, 2018

SRC-3 shushes stem cells

Sep. 5, 2018

European Commission approves Cablivi for acquired thrombotic thrombocytopenic purpura

Sep. 3, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 10, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Orexin OX2 receptor agonists disclosed in Vertex Pharmaceuticals patent
BioWorld Science
Vertex Pharmaceuticals Inc. has patented new macrocyclic sulfonamide orexin OX2 receptor agonists potentially useful for the treatment of amyotrophic lateral...